Download

Full Text

• Davey, R.T., Jr.; Bhat, N.; Yoder, C.; Chun, T.W.; Metcalf, J.A.; Dewar, R.; Natarajan, V.; Lempicki, R.A.; Adelsberger, J.W.; Miller, K.D.; et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc. Natl. Acad. Sci. USA 1999, 96, 15109-15114. [CrossRef] [PubMed]
• Whitney, J.B.; Hill, A.L.; Sanisetty, S.; Penaloza-MacMaster, P.; Liu, J.; Shetty, M.; Parenteau, L.; Cabral, C.; Shields, J.; Blackmore, S.; et al. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature 2014, 512, 74-77. [CrossRef] [PubMed]
• Darcis, G.; Van Driessche, B.; Van Lint, C. HIV latency: Should we shock or lock?. Trends Immunol. 2017, 38, 217-228. [CrossRef] [PubMed]
• Colby, D.J.; Trautmann, L.; Pinyakorn, S.; Leyre, L.; Pagliuzza, A.; Kroon, E.; Rolland, M.; Takata, H.; Buranapraditkun, S.; Intasan, J.; et al. Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection. Nat. Med. 2018, 24, 923-926. [CrossRef] [PubMed]
• Wong, J.K.; Yukl, S.A. Tissue reservoirs of HIV. Curr. Opin. HIV AIDS 2016, 11, 362-370. [CrossRef]
• Darcis, G.; Bouchat, S.; Kula, A.; Van Driessche, B.; Delacourt, N.; Vanhulle, C.; Avettand-Fenoel, V.; De Wit, S.; Rohr, O.; Rouzioux, C.; et al. Reactivation capacity by latency-reversing agents ex vivo correlates with the size of the HIV-1 reservoir. AIDS 2017, 31, 181-189. [CrossRef]
• Chen, H.C.; Martinez, J.P.; Zorita, E.; Meyerhans, A.; Filion, G.J. Position effects influence HIV latency reversal. Nat. Struct. Mol. Biol. 2017, 24, 47-54. [CrossRef]
• Chun, T.W.; Carruth, L.; Finzi, D.; Shen, X.; DiGiuseppe, J.A.; Taylor, H.; Hermankova, M.; Chadwick, K.; Margolick, J.; Quinn, T.C.; et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997, 387, 183-188. [CrossRef]
• Khoury, G.; Darcis, G.; Lee, M.Y.; Bouchat, S.; Van Driessche, B.; Purcell, D.F.J.; Van Lint, C. The molecular biology of HIV latency. Adv. Exp. Med. Biol. 2018, 1075, 187-212. [CrossRef]
• Buchholz, F.; Hauber, J. In vitro evolution and analysis of HIV-1 LTR-specific recombinases. Methods 2011, 53, 102-109. [CrossRef]
• Karpinski, J.; Hauber, I.; Chemnitz, J.; Schafer, C.; Paszkowski-Rogacz, M.; Chakraborty, D.; Beschorner, N.; Hofmann-Sieber, H.; Lange, U.C.; Grundhoff, A.; et al. Directed evolution of a recombinase that excises the provirus of most HIV-1 primary isolates with high specificity. Nat. Biotechnol. 2016, 34, 401-409. [CrossRef] [PubMed]
• Sarkar, I.; Hauber, I.; Hauber, J.; Buchholz, F. HIV-1 proviral DNA excision using an evolved recombinase. Science 2007, 316, 1912-1915. [CrossRef] [PubMed]
• Benjamin, R.; Berges, B.K.; Solis-Leal, A.; Igbinedion, O.; Strong, C.L.; Schiller, M.R. TALEN gene editing takes aim on HIV. Hum. Genet. 2016, 135, 1059-1070. [CrossRef] [PubMed]
• Manjunath, N.; Yi, G.; Dang, Y.; Shankar, P. Newer gene editing technologies toward HIV gene therapy. Viruses 2013, 5, 2748-2766. [CrossRef] [PubMed]
• Stone, D.; Kiem, H.P.; Jerome, K.R. Targeted gene disruption to cure HIV. Curr. Opin. HIV AIDS 2013, 8, 217-223. [CrossRef] [PubMed]
• Stone, D.; Niyonzima, N.; Jerome, K.R. Genome editing and the next generation of antiviral therapy. Hum. Genet. 2016, 135, 1071-1082. [CrossRef] [PubMed]
• Cho, S.W.; Kim, S.; Kim, J.M.; Kim, J.S. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat. Biotechnol. 2013, 31, 230-232. [CrossRef] [PubMed]
• Hsu, P.D.; Lander, E.S.; Zhang, F. Development and applications of CRISPR-Cas9 for genome engineering. Cell 2014, 157, 1262-1278. [CrossRef] [PubMed]
• Wang, G.; Zhao, N.; Berkhout, B.; Das, A.T. CRISPR-Cas based antiviral strategies against HIV-1. Virus Res. 2018, 244, 321-332. [CrossRef] [PubMed]
• Darcis, G.; Das, A.T.; Berkhout, B. Tackling HIV persistence: Pharmacological versus CRISPR-based shock strategies. Viruses 2018, 10. [CrossRef] [PubMed]
• Soppe, J.A.; Lebbink, R.J. Antiviral goes viral: Harnessing CRISPR/Cas9 to combat viruses in humans. Trends Microbiol. 2017, 25, 833-850. [CrossRef]
• Wang, G.; Zhao, N.; Berkhout, B.; Das, A.T. CRISPR-Cas9 can inhibit HIV-1 replication but NHEJ repair facilitates virus escape. Mol. Ther. 2016, 24, 522-526. [CrossRef] [PubMed]
• Liang, C.; Wainberg, M.A.; Das, A.T.; Berkhout, B. CRISPR/Cas9: A double-edged sword when used to combat HIV infection. Retrovirology 2016, 13, 37. [CrossRef] [PubMed]
• Wang, Z.; Pan, Q.; Gendron, P.; Zhu, W.; Guo, F.; Cen, S.; Wainberg, M.A.; Liang, C. CRISPR/Cas9-derived mutations both inhibit HIV-1 replication and accelerate viral escape. Cell Rep. 2016, 15, 481-489. [CrossRef] [PubMed]
• Wang, G.; Zhao, N.; Berkhout, B.; Das, A.T. A Combinatorial CRISPR-Cas9 Attack on HIV-1 DNA Extinguishes All Infectious Provirus in Infected T Cell Cultures. Cell Rep. 2016, 17, 2819-2826. [CrossRef] [PubMed]
• Lebbink, R.J.; de Jong, D.C.; Wolters, F.; Kruse, E.M.; van Ham, P.M.; Wiertz, E.J.; Nijhuis, M. A combinational CRISPR/Cas9 gene-editing approach can halt HIV replication and prevent viral escape. Sci. Rep. 2017, 7, 41968. [CrossRef] [PubMed]
• Geretti, A.M. HIV-1 subtypes: Epidemiology and significance for HIV management. Curr. Opin. Infect. Dis. 2006, 19, 1-7. [CrossRef]
• Robertson, D.L.; Anderson, J.P.; Bradac, J.A.; Carr, J.K.; Foley, B.; Funkhouser, R.K.; Gao, F.; Hahn, B.H.; Kalish, M.L.; Kuiken, C.; et al. HIV-1 nomenclature proposal. Science 2000, 288, 55-56. [CrossRef]
• Doench, J.G.; Fusi, N.; Sullender, M.; Hegde, M.; Vaimberg, E.W.; Donovan, K.F.; Smith, I.; Tothova, Z.; Wilen, C.; Orchard, R.; et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat. Biotechnol. 2016, 34, 184-191. [CrossRef] [PubMed]
• Hsu, P.D.; Scott, D.A.; Weinstein, J.A.; Ran, F.A.; Konermann, S.; Agarwala, V.; Li, Y.; Fine, E.J.; Wu, X.; Shalem, O.; et al. DNA targeting specificity of RNA-guided Cas9 nucleases. Nat. Biotechnol. 2013, 31, 827-832. [CrossRef]
• Qi, L.S.; Larson, M.H.; Gilbert, L.A.; Doudna, J.A.; Weissman, J.S.; Arkin, A.P.; Lim, W.A. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 2013, 152, 1173-1183. [CrossRef] [PubMed]
• Roychoudhury, P.; De Silva Feelixge, H.; Reeves, D.; Mayer, B.T.; Stone, D.; Schiffer, J.T.; Jerome, K.R. Viral diversity is an obligate consideration in CRISPR/Cas9 designs for targeting the HIV reservoir. BMC Biol. 2018, 16, 75. [CrossRef] [PubMed]
• Dampier, W.; Sullivan, N.T.; Mell, J.C.; Pirrone, V.; Ehrlich, G.D.; Chung, C.H.; Allen, A.G.; DeSimone, M.; Zhong, W.; Kercher, K.; et al. Broad-spectrum and personalized guide RNAs for CRISPR/Cas9 HIV-1 therapeutics. AIDS Res. Hum. Retroviruses 2018, 34, 950-960. [CrossRef] [PubMed]
• Pham, H.; Kearns, N.A.; Maehr, R. Transcriptional Regulation with CRISPR/Cas9 Effectors in Mammalian Cells. Methods Mol. Biol. 2016, 1358, 43-57. [CrossRef] [PubMed]
• Sanjana, N.E.; Shalem, O.; Zhang, F. Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods 2014, 11, 783-784. [CrossRef]
• Das, A.T.; Harwig, A.; Berkhout, B. The HIV-1 Tat protein has a versatile role in activating viral transcription. J. Virol. 2011, 85, 9506-9516. [CrossRef] [PubMed]
• Darcis, G.; Kula, A.; Bouchat, S.; Fujinaga, K.; Corazza, F.; Ait-Ammar, A.; Delacourt, N.; Melard, A.; Kabeya, K.; Vanhulle, C.; et al. An in-depth comparison of latency-reversing agent combinations in various in vitro and ex vivo HIV-1 latency models identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to potently reactivate viral rene expression. PLoS Pathogens. 2015, 11, e1005063. [CrossRef] [PubMed]
• Ter Brake, O.; Konstantinova, P.; Ceylan, M.; Berkhout, B. Silencing of HIV-1 with RNA interference: A multiple shRNA approach. Mol. Ther. 2006, 14, 883-892. [CrossRef] [PubMed]
• Herrera-Carrillo, E.; Berkhout, B. The impact of HIV-1 genetic diversity on the efficacy of a combinatorial RNAi-based gene therapy. Gene Ther. 2015, 22, 485-495. [CrossRef] [PubMed]
• Pollakis, G.; Abebe, A.; Kliphuis, A.; Chalaby, M.I.; Bakker, M.; Mengistu, Y.; Brouwer, M.; Goudsmit, J.; Schuitemaker, H.; Paxton, W.A. Phenotypic and genotypic comparisons of CCR5- and CXCR4-tropic human immunodeficiency virus type 1 biological clones isolated from subtype C-infected individuals. J. Virol. 2004, 78, 2841-2852. [CrossRef]
• Herrera-Carrillo, E.; Paxton, W.A.; Berkhout, B. The search for a T cell line for testing novel antiviral strategies against HIV-1 isolates of diverse receptor tropism and subtype origin. J. Virol. Methods 2014, 203, 88-96. [CrossRef] [PubMed]
• Jeeninga, R.E.; Jan, B.; van den Berg, H.; Berkhout, B. Construction of doxycyline-dependent mini-HIV-1 variants for the development of a virotherapy against leukemias. Retrovirology 2006, 3, 64. [CrossRef] [PubMed]
• Dampier, W.; Sullivan, N.T.; Chung, C.H.; Mell, J.C.; Nonnemacher, M.R.; Wigdahl, B. Designing broad-spectrum anti-HIV-1 gRNAs to target patient-derived variants. Sci. Rep. 2017, 7, 14413. [CrossRef] [PubMed]
• Xu, X.; Duan, D.; Chen, S.J. CRISPR-Cas9 cleavage efficiency correlates strongly with target-sgRNA folding stability: From physical mechanism to off-target assessment. Sci. Rep. 2017, 7, 143. [CrossRef] [PubMed]
• Ryan, D.E.; Taussig, D.; Steinfeld, I.; Phadnis, S.M.; Lunstad, B.D.; Singh, M.; Vuong, X.; Okochi, K.D.; McCaffrey, R.; Olesiak, M.; et al. Improving CRISPR-Cas specificity with chemical modifications in single-guide RNAs. Nucleic Acids Res. 2018, 46, 792-803. [CrossRef]
• Chuai, G.H.; Wang, Q.L.; Liu, Q. In silico meets in vivo: Towards computational CRISPR-based sgRNA design. Trends Biotechnol. 2017, 35, 12-21. [CrossRef]
• Tycko, J.; Myer, V.E.; Hsu, P.D. Methods for optimizing CRISPR-Cas9 genome editing specificity. Mol. Cell 2016, 63, 355-370. [CrossRef]
• Schwartz, C.; Bouchat, S.; Marban, C.; Gautier, V.; Van Lint, C.; Rohr, O.; Le Douce, V. On the way to find a cure: Purging latent HIV-1 reservoirs. Biochem. Pharmacol. 2017, 146, 10-22. [CrossRef]
• Darcis, G.; Van Driessche, B.; Bouchat, S.; Kirchhoff, F.; Van Lint, C. Molecular control of HIV and SIV latency. Curr Top. Microbiol. Immunol. 2018, 417, 1-22. [CrossRef]
• Darcis, G.; Coombs, R.W.; Van Lint, C. Exploring the anatomical HIV reservoirs: Role of the testicular tissue. AIDS 2016, 30, 2891-2893. [CrossRef]
• Campbell, L.A.; Coke, L.M.; Richie, C.T.; Fortuno, L.V.; Park, A.Y.; Harvey, B.K. Gesicle-mediated delivery of CRISPR/Cas9 ribonucleoprotein complex for inactivating the HIV provirus. Mol. Ther. 2019, 27, 151-163. [CrossRef] [PubMed]
• Lino, C.A.; Harper, J.C.; Carney, J.P.; Timlin, J.A. Delivering CRISPR: A review of the challenges and approaches. Drug Deliv. 2018, 25, 1234-1257. [CrossRef] [PubMed]
• Bella, R.; Kaminski, R.; Mancuso, P.; Young, W.B.; Chen, C.; Sariyer, R.; Fischer, T.; Amini, S.; Ferrante, P.; Jacobson, J.M.; et al. Removal of HIV DNA by CRISPR from patient blood engrafts in humanized mice. Mol. Ther. Nucleic Acids 2018, 12, 275-282. [CrossRef] [PubMed]
• Wang, L.; Li, F.; Dang, L.; Liang, C.; Wang, C.; He, B.; Liu, J.; Li, D.; Wu, X.; Xu, X.; et al. In vivo delivery systems for therapeutic genome editing. Int. J. Mol. Sci. 2016, 17. [CrossRef] [PubMed]
• Ran, F.A.; Cong, L.; Yan, W.X.; Scott, D.A.; Gootenberg, J.S.; Kriz, A.J.; Zetsche, B.; Shalem, O.; Wu, X.; Makarova, K.S.; et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature 2015, 520, 186-191. [CrossRef] [PubMed]
• Yin, C.; Zhang, T.; Qu, X.; Zhang, Y.; Putatunda, R.; Xiao, X.; Li, F.; Xiao, W.; Zhao, H.; Dai, S.; et al. In vivo excision of HIV-1 provirus by saCas9 and multiplex single-guide RNAs in animal models. Mol. Ther. 2017, 25, 1168-1186. [CrossRef]
• Gao, Z.; Herrera-Carrillo, E.; Berkhout, B. A single H1 promoter can drive both guide RNA and endonuclease expression in the CRISPR-Cas9 system. Mol. Ther. Nucleic Acids 2018, 14, 32-40. [CrossRef]
• Bayat, H.; Modarressi, M.H.; Rahimpour, A. The conspicuity of CRISPR-Cpf1 system as a significant breakthrough in genome editing. Curr. Microbiol. 2018, 75, 107-115. [CrossRef]
• Gao, Z.; Herrera-Carrillo, E.; Berkhout, B. Improvement of the CRISPR-Cpf1 system with ribozyme-processed crRNA. RNA Biol. 2018, 15, 1458-1467. [CrossRef]